BEAM Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 60379 min ago

@ $35.38

Išleistas: 21 kov. 2024 @ 20:07

Grąža: -36.80%

Ankstesnis signalas: kov. 20 - 17:15

Ankstesnis signalas: Pardavimas

Grąža: 1.94 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 19:26):

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...

Stats
Šios dienos apimtis	393 126
Vidutinė apimtis	1.52M
Rinkos kapitalizacija	1.83B
EPS	$0 ( 2024-02-27 )
Kita pelno data	( $-1.450 ) 2024-05-08
Last Dividend	$0.225 ( 2014-02-04 )
Next Dividend	$0 ( N/A )
P/E	-13.00
ATR14	$0.0360 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Burrell Terry-ann	Buy	12 500	Common Stock
2024-04-26	Burrell Terry-ann	Buy	25 000	Stock Option (Right to Buy)
2024-04-01	Simon Amy	Sell	7 157	Common Stock
2024-04-02	Simon Amy	Sell	16 530	Common Stock
2024-04-01	Bellon Christine	Sell	3 401	Common Stock

INSIDER POWER
-11.08
Last 98 transactions
Buy: 1 537 714 \| Sell: 1 873 404

Tūris Koreliacija

Ilgas: 0.02 (neutral)

Trumpas: 0.77 (moderate)

Signal:(52.998) Neutral

Beam Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TUEM	0.951
TWST	0.942
SGMO	0.93
CSSE	0.929
ROST	0.927
MDRX	0.926
GRPN	0.924
RKDA	0.924
HMST	0.923
AFIB	0.923

10 Labiausiai neigiamai susiję koreliacijos
WIRE	-0.933
CPTA	-0.928
TYHT	-0.928
ZGNX	-0.926
HTBI	-0.92
VC	-0.92
PAE	-0.919
SGEN	-0.919
RAM	-0.916
EBSB	-0.91

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Beam Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.03
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.11
( neutral )

-0.58
( weak negative )

-0.29
( neutral )

Beam Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$377.71M
Bruto pelnas:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2023
Pajamos:	$377.71M
Bruto pelnas:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2022
Pajamos:	$60.92M
Bruto pelnas:	$38.34M (62.94 %)
EPS:	$-3.76

FY	2021
Pajamos:	$51.84M
Bruto pelnas:	$51.84M (100.00 %)
EPS:	$-5.77

Financial Reports:

No articles found.

Beam Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Beam Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.443 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.190	2011-11-07
Last Dividend	$0.225	2014-02-04
Next Dividend	$0	N/A
Payout Date	2014-03-03
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$2.16	--
Avg. Dividend % Per Year	0.00%	--
Score	1.6	--
Div. Sustainability Score	1.443
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.60

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.318	1.500	-6.36	-9.54	[0 - 0.5]
returnOnAssetsTTM	-0.0823	1.200	-2.74	-3.29	[0 - 0.3]
returnOnEquityTTM	-0.144	1.500	-2.71	-4.07	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.89	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.79	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.12	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.119	-1.500	8.02	-10.00	[0 - 0.6]
interestCoverageTTM	-5.10	1.000	-3.00	-3.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
freeCashFlowPerShareTTM	-2.26	2.00	-1.131	-2.26	[0 - 20]
debtEquityRatioTTM	0.176	-1.500	9.29	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.928	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.467	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.862	1.000	-5.90	-5.90	[0.2 - 2]
assetTurnoverTTM	0.259	0.800	-1.608	-1.287	[0.5 - 2]
Total Score				1.443

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-14.64	1.000	-1.579	0	[1 - 100]
returnOnEquityTTM	-0.144	2.50	-1.744	-4.07	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.26	2.00	-0.754	-2.26	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.274	1.500	-5.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.395	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.64

Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.